Remove clinical cardiovascular-health
article thumbnail

WHO adds cardiovascular polypill to List of Essential Medicines

Hospital Pharmacy Europe

The World Health Organization (WHO) has added a cardiovascular polypill, which includes acetylsalicylic acid, ramipril and atorvastatin, to its List of Essential Medicines. The WHO defines essential medicines as ‘those that satisfy the priority health care needs of a population. of patients in the polypill group and 12.7%

Dosage 96
article thumbnail

AI-powered personalised medicine project launches to optimise CVD treatment

Hospital Pharmacy Europe

A new international project aiming to use artificial intelligence (AI) and genomics data to personalise therapies for patients with cardiovascular disease (CVD) has been announced. The unique picture we generate will then form the basis for improving cardiovascular health and wellbeing.’

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Is drinking bad for your cholesterol?

The Checkup by Singlecare

The health issue that arises for many people is when levels get out of whack—meaning, your “bad” cholesterol is too high while the “good” kind is too low. It’s why high cholesterol can increase your risk of cardiovascular problems, like high blood pressure, coronary heart disease, or a heart attack.

111
111
article thumbnail

Digital interventions cut heart failure mortality, study shows

pharmaphorum

An analysis of 10 clinical trials of digital health interventions targeted at patients recently hospitalised for acute heart failure has found they improve outcomes compared to standard care. with the digital approaches, a reduction of 18%, while cardiovascular mortality was 20% lower (9.6% with usual care to 8.5%

Hospitals 139
article thumbnail

STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch

STAT

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Novo Nordisk is conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health.

article thumbnail

First NICE-recommended treatment for chronic heart failure

European Pharmaceutical Review

Final draft guidance has been published for the first National Institute for Health and Care Excellence (NICE)-recommended treatment for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction. The study enrolled 6,263 randomised patients. This was reported as 16.4 percent in the dapagliflozin group and 19.5

Hospitals 104
article thumbnail

STAT+: What to know about this summer’s landmark Wegovy heart health study

STAT

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits. Continue to STAT+ to read the full story…